RadNet (RDNT) Expected to Post Earnings on Sunday

RadNet (NASDAQ:RDNT) is projected to announce its Q2 2026 results before the market opens on Sunday, August 9th. Analysts expect RadNet to announce earnings of $0.1886 per share and revenue of $610.0110 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 10:30 AM ET.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Monday, May 11th. The medical research company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The firm had revenue of $575.63 million for the quarter, compared to analysts’ expectations of $557.93 million. During the same quarter in the prior year, the business earned ($0.50) earnings per share. The company’s quarterly revenue was up 22.1% on a year-over-year basis. On average, analysts expect RadNet to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet Trading Up 1.7%

Shares of NASDAQ RDNT opened at $63.78 on Friday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $5.02 billion, a PE ratio of -354.31 and a beta of 1.37. RadNet has a twelve month low of $50.76 and a twelve month high of $85.84. The stock has a fifty day simple moving average of $59.54 and a 200-day simple moving average of $61.89.

Insider Buying and Selling at RadNet

In related news, Director David L. Swartz sold 2,699 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $53.89, for a total transaction of $145,449.11. Following the completion of the transaction, the director directly owned 177,013 shares of the company’s stock, valued at $9,539,230.57. The trade was a 1.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Cornelis Wesdorp sold 4,750 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $58.11, for a total value of $276,022.50. Following the sale, the chief executive officer owned 69,075 shares in the company, valued at approximately $4,013,948.25. This trade represents a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On RadNet

Several hedge funds and other institutional investors have recently made changes to their positions in RDNT. AQR Capital Management LLC raised its holdings in RadNet by 5.4% in the first quarter. AQR Capital Management LLC now owns 6,846 shares of the medical research company’s stock valued at $340,000 after acquiring an additional 350 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in RadNet by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,341 shares of the medical research company’s stock worth $1,956,000 after acquiring an additional 1,699 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in RadNet by 563.4% during the 1st quarter. Jones Financial Companies Lllp now owns 1,705 shares of the medical research company’s stock worth $85,000 after acquiring an additional 1,448 shares in the last quarter. United Services Automobile Association acquired a new position in RadNet during the 1st quarter worth approximately $216,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of RadNet by 2.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 440,543 shares of the medical research company’s stock valued at $21,904,000 after purchasing an additional 8,762 shares during the last quarter. Hedge funds and other institutional investors own 77.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays lowered their target price on RadNet from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, May 20th. Zacks Research lowered shares of RadNet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research report on Friday. Finally, Weiss Ratings lowered shares of RadNet from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.43.

RadNet Company Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.